14 results about "Periostin" patented technology

The invention discloses an oligonucleotide intracellular nano delivery system based on polypeptide modification and application thereof. The system is composed of a periostin targeting sequence (SDSSD), a matrix metalloproteinase 2 (MMP2) response sequence (GPAGLLG), a cell penetrating sequence (RRRRRRRR, R9), a reactive oxygen species (ROS) scavenging and adhesion enhancing group (Gly-DOPA)) and a terminal dibenzocyclooctyne (DBCO) modified engineered polypeptide SDSSD-PEG5-YGFGG-GPAGLLG-R9-(G-DOPA) 3-K4-C-DBCO, and a target oligonucleotide miRNA-26a-A5-Azido modified by 5-polyadenylic acid (AAAAA) and an azide group (Azido), and the target oligonucleotide miRNA-26a-A5-Azido, the target oligonucleotide and assembling through a click chemical reaction and a non-covalent interaction. The nano system has good bone targeting, enzyme responsiveness, intracellular delivery effect and biological safety, can realize stable and efficient delivery of therapeutic oligonucleotides in vivo, and significantly improves the utilization efficiency and therapeutic potential of oligonucleotides. The oligonucleotide intracellular nano delivery system has a wide application prospect in the fields of clinical transformation and precise treatment of oligonucleotide drugs.

The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.

The invention belongs to the technical field of biological medicines, and particularly discloses application of recombinant human periostin in preparation of a medicine for improving intervertebral disc degeneration. The invention provides application of recombinant human periostin in preparation of a medicine for improving intervertebral disc degeneration. The invention provides an application of recombinant human periostin in preparation of a medicine for improving intervertebral disc degeneration, and the medicine can improve the intervertebral disc degeneration by inhibiting ferroptosis of intervertebral disc nucleus pulposus cells and enhancing the total antioxidant capacity of the intervertebral disc nucleus pulposus cells.

The present invention provides a biomarker for the detection of glioma microenvironment (TME), comprising a serum marker selected from any one or more of annexin A1 (ANXA1), annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2), and a pathological marker selected from any one or more of Annexin A1 (ANXA1), Annexin A2 (ANXA2), matrix metalloproteinase 14 (MMP14) and potential transforming growth factor beta binding protein 2 (LTBP2); the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and a phospholipase A2 group IIA (PLA2G2A), and the pathological marker is selected from one or more of periostin (POSTN), lactoferrin (LTF) and phospholipase A2 group IIA (PLA2G2A). The invention also provides an application of the biomarker in diagnosis of glioma. The invention provides an innovative idea and a biomarker for non-invasive diagnosis of glioma, and can be used for prognosis and malignant diagnosis of glioma.

Provided is a recombinant adeno-associated virus vector which includes: a polynucleotide comprising at least one sequence selected from the group consisting of a periostin promoter sequence, a collagen 1a2 promoter sequence, and a cartilage oligomer matrix protein (COMP) promoter sequence; and an AAV-DJ capsid protein. The collagen 1a2 promoter sequence is any one of (2-1) to (2-4) described in the description. The cartilage oligomer matrix protein (COMP) promoter sequence is any one of (3-1) to (3-4) described in the description.

A pharmaceutical composition containing a stem cell secretion, and a pharmaceutically acceptable excipient thereof. The protein in the stem cell secretion comprises one, two or three proteins selected from a group consisting of a pigment epithelium-derived factor (PEDF), a tissue inhibitor of metalloproteinase 1 (TIMP-1), a secreted protein acidic and rich in cysteine (SPARC), an α2-HS glycoprotein (AHSG), a periostin (POSTN), a decorin (DCN), the retinoic acid receptor responder 2 (RARRES2), the glia-derived nexin (GDN), the Sparc / osteonectin, cwcv and kazal like domains proteoglycan 1 (SPOCK1), and the follistatin-like 1 (FSTL1). The pharmaceutical composition is used for treating degenerative ocular diseases including retinal degeneration, retinitis pigmentosa, glaucoma, macular degeneration, etc.

The present application belongs to the field of biomedical and cosmetic technology, and particularly relates to the application of periostin in the preparation of preparations for promoting the activity of hair follicle cells or for preventing and treating alopecia. The present application first discovers that periostin has the activity of regulating hair follicle papilla cells, hair matrix cells and outer root sheath cells, can promote the proliferation of hair follicle papilla cells, hair matrix cells and outer root sheath cells, improve the hair induction ability of hair follicle papilla cells, and promote the hair follicle cycle transformation, hair growth and thickening, and can be applied to the preparation of preparations for treating alopecia.

The aim is to prevent and / or improve skin conditions that negatively affect skin appearance, such as wrinkles and sagging, by promoting the formation of cyclic collagen. [Solution] Screening was conducted on the expression of proteoglycan-related genes involved in proteoglycan formation, and it was found that rosehip extract or safflower extract increases the gene expression of persican and periostin, which are proteoglycan-related genes. Thus, rosehip extract or safflower extract was identified as a promoter of cyclic collagen formation.

The invention is applicable to the technical field of biology, and provides bionic hydrogel for culturing tongue cancer organoid and application. The bionic hydrogel is prepared by taking type I collagen, alginate and periostin polypeptide as cores according to the microenvironment characteristics of tongue cancer, and is adapted to the mechanical characteristics of tongue squamous cell carcinoma tissues and the three-dimensional growth space requirements of organoids in the physical aspect; in the biochemical level, the tongue cancer microenvironment is accurately simulated by virtue of the effects of promoting cell adhesion of the I-type collagen and maintaining the dryness of the cancer cells by virtue of the periostin polypeptide, so that a complete culture method is formed. The bionic hydrogel is stable in property and capable of supporting the culture requirement for a long time and enhancing the interaction between cells and a matrix so as to improve the cell adhesion capacity, the cultured tongue cancer organoid can well maintain the heterogeneity and tumor malignant phenotype of tongue cancer cells, and the bionic effect of the organoid is optimized. The result provides a high-precision in-vitro model for tongue cancer drug screening, chemotherapy sensitivity prediction and individualized treatment, and has practical application value.

The application belongs to the technical field of biotechnology, and provides a biomimetic hydrogel for tongue cancer organoid culture and application.According to the characteristics of the tongue cancer microenvironment, the biomimetic hydrogel is prepared by taking collagen type I, alginate and periostin polypeptide as the core, the mechanical characteristics of tongue squamous cell carcinoma tissue and the three-dimensional growth space requirements of organoids are adapted on the physical level, the tongue cancer microenvironment is precisely simulated on the biochemical level by relying on the cell adhesion promotion of collagen type I and the role of periostin polypeptide in maintaining the stemness of cancer cells, and a complete culture method is formed.The biomimetic hydrogel is stable in nature, can support the culture requirements for a long time, can enhance the interaction between cells and the matrix to improve the cell adhesion capacity, and the tongue cancer organoids cultured by the biomimetic hydrogel can well retain the heterogeneity of tongue cancer cells and the malignant phenotype of tumors, and the biomimetic effect of the organoids is optimized.The achievement provides a high-precision in-vitro model for tongue cancer drug screening, chemotherapy sensitivity prediction and individualized treatment, and has practical application value.

The invention belongs to the technical field of biological medicines, and particularly discloses application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The invention provides application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The invention provides application of low-concentration recombinant human periostin in preparation of a medicine for treating intervertebral disc degeneration. The low-concentration recombinant human periostin can remarkably reduce the death rate of intervertebral disc nucleus pulposus cells induced by TNF-alpha, effectively relieve oxidative stress injury, up-regulate the expression of Collagen II and Aggrecan, down-regulate the expression of MMP 13, promote cell proliferation and treat intervertebral disc degeneration.

In the present study, the Inventors propose that characterizing fibroblasts derived from individuals of very different ages, regarding their Structure, Inflammation, and Metabolism (SIM) signatures, and assessing their stress response to challenges mimicking life stresses, would enhance their understanding of the aging process and frailty syndrome and intrinsic capacity. To address these inquiries, they used fibroblasts obtained from skin biopsies of 133 male and female volunteers from the INSPIRE human translational cohort (INSPIRE-T cohort) 21, spanning ages 20 to 96 years, and encompassing various frailty statuses (robust, pre-frail, frail). Through this thorough characterization, they pinpointed markers specifically associated with aging, intrinsic capacity or indicators of frailty syndrome. The present invention relates to an in vitro method for predicting intrinsic capacity decline and / or frailty in a subject comprising the step of determining the level of extracellular periostin in a sample comprising fibroblasts obtained from said subject.

Methods for preventing or treating periodontal disease or a dislocated traumatic tooth, for for regenerating periodontium, and for promoting expression of any one or more genes of bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), cementum attachment protein (CAP), collagen type III (COL3), and periostin, are disclosed. The methods include administering an effective amount of a peptide comprising the amino acid sequence of SEQ ID NO: 29 or a pharmaceutically acceptable salt thereof or a composition containing the peptide of a salt thereof.

The invention belongs to the technical field of biomedicine and cosmetics, and particularly relates to application of periostin in preparation of a preparation for promoting hair follicle cell activity or preventing and treating alopecia. It is found for the first time that periostin has the activity of adjusting hair follicle hair papilla cells, hair parent cells and outer root sheath cells, proliferation of the hair papilla cells, the hair parent cells and the outer root sheath cells can be promoted, the hair induction capacity of the hair papilla cells is improved, hair follicle cycle transformation and hair growth and thickening are promoted, and the hair growth rate is increased. The traditional Chinese medicine composition can be used for preparing preparations for treating alopecia.